Key Points
- CEO Christopher Anzalone sold 85,000 shares of Arrowhead on Dec. 17 at an average price of $64.04 for $5.44M, leaving him with 3,831,957 shares (a reported 2.17% reduction in his ownership) valued at about $245.4M.
- Anzalone also sold shares on Dec. 15–16 (130,000 and 54,298 shares), meaning insider sales over those three days totaled roughly 269,298 shares for about $17.8M; Arrowhead is a $9.26B biotech with a 52-week range of $9.57–$72.36 and a MarketBeat consensus rating of "Moderate Buy" (price target ~$61.89).
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 85,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $64.04, for a total value of $5,443,400.00. Following the transaction, the chief executive officer owned 3,831,957 shares in the company, valued at approximately $245,398,526.28. This represents a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Christopher Richard Anzalone also recently made the following trade(s):
- On Tuesday, December 16th, Christopher Richard Anzalone sold 54,298 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $62.58, for a total value of $3,397,968.84.
- On Monday, December 15th, Christopher Richard Anzalone sold 130,000 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $68.85, for a total value of $8,950,500.00.
Arrowhead Pharmaceuticals Price Performance
Shares of ARWR opened at $68.16 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86. The firm has a market capitalization of $9.26 billion, a PE ratio of -851.89 and a beta of 1.28. The stock has a 50 day simple moving average of $48.48 and a 200 day simple moving average of $31.11. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $9.57 and a 52-week high of $72.36.
Wall Street Analyst Weigh In
A number of analysts have recently commented on the company. Morgan Stanley boosted their price target on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an "equal weight" rating in a report on Wednesday, November 26th. Weiss Ratings restated a "sell (d-)" rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. HC Wainwright upped their price target on Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the stock a "buy" rating in a research report on Tuesday, December 2nd. Royal Bank Of Canada raised their price target on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an "outperform" rating in a research note on Thursday, December 11th. Finally, The Goldman Sachs Group boosted their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a "neutral" rating in a research report on Thursday, November 20th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $61.89.
Check Out Our Latest Research Report on ARWR
Hedge Funds Weigh In On Arrowhead Pharmaceuticals
Several hedge funds and other institutional investors have recently made changes to their positions in the company. iSAM Funds UK Ltd bought a new stake in Arrowhead Pharmaceuticals during the third quarter worth $29,000. Virtus Advisers LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at about $34,000. Salomon & Ludwin LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at about $34,000. Nisa Investment Advisors LLC lifted its stake in Arrowhead Pharmaceuticals by 75.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 1,308 shares during the last quarter. Finally, Federated Hermes Inc. bought a new position in Arrowhead Pharmaceuticals during the third quarter worth about $52,000. 62.61% of the stock is owned by institutional investors.
About Arrowhead Pharmaceuticals
(
Get Free Report)
Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.
The company's pipeline includes multiple candidates in various stages of development.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
